Last reviewed · How we verify

Vasopressin intravenous infusion

University of Sao Paulo · FDA-approved active Small molecule

Vasopressin intravenous infusion is a Vasopressor agent; antidiuretic hormone Small molecule drug developed by University of Sao Paulo. It is currently FDA-approved for Variceal bleeding (esophageal varices), Hypotension/shock (septic shock, cardiogenic shock), Central diabetes insipidus. Also known as: Arginine Vasopressin, ADH, Pitressin.

Vasopressin is a peptide hormone that binds to vasopressin receptors (V1 and V2) to increase vascular tone, blood pressure, and water reabsorption in the kidneys.

Vasopressin is a peptide hormone that binds to vasopressin receptors (V1 and V2) to increase vascular tone, blood pressure, and water reabsorption in the kidneys. Used for Variceal bleeding (esophageal varices), Hypotension/shock (septic shock, cardiogenic shock), Central diabetes insipidus.

At a glance

Generic nameVasopressin intravenous infusion
Also known asArginine Vasopressin, ADH, Pitressin
SponsorUniversity of Sao Paulo
Drug classVasopressor agent; antidiuretic hormone
TargetVasopressin receptor V1a, V1b, and V2
ModalitySmall molecule
Therapeutic areaCardiovascular; Endocrinology
PhaseFDA-approved

Mechanism of action

Vasopressin acts as a potent vasoconstrictor through V1 receptor activation on vascular smooth muscle, increasing systemic vascular resistance and blood pressure. It also activates V2 receptors in the renal collecting duct to promote aquaporin-2 water channel insertion, increasing water reabsorption and reducing urine output. These combined effects make it useful in treating hypotension and variceal bleeding.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Vasopressin intravenous infusion

What is Vasopressin intravenous infusion?

Vasopressin intravenous infusion is a Vasopressor agent; antidiuretic hormone drug developed by University of Sao Paulo, indicated for Variceal bleeding (esophageal varices), Hypotension/shock (septic shock, cardiogenic shock), Central diabetes insipidus.

How does Vasopressin intravenous infusion work?

Vasopressin is a peptide hormone that binds to vasopressin receptors (V1 and V2) to increase vascular tone, blood pressure, and water reabsorption in the kidneys.

What is Vasopressin intravenous infusion used for?

Vasopressin intravenous infusion is indicated for Variceal bleeding (esophageal varices), Hypotension/shock (septic shock, cardiogenic shock), Central diabetes insipidus.

Who makes Vasopressin intravenous infusion?

Vasopressin intravenous infusion is developed and marketed by University of Sao Paulo (see full University of Sao Paulo pipeline at /company/university-of-sao-paulo).

Is Vasopressin intravenous infusion also known as anything else?

Vasopressin intravenous infusion is also known as Arginine Vasopressin, ADH, Pitressin.

What drug class is Vasopressin intravenous infusion in?

Vasopressin intravenous infusion belongs to the Vasopressor agent; antidiuretic hormone class. See all Vasopressor agent; antidiuretic hormone drugs at /class/vasopressor-agent-antidiuretic-hormone.

What development phase is Vasopressin intravenous infusion in?

Vasopressin intravenous infusion is FDA-approved (marketed).

What are the side effects of Vasopressin intravenous infusion?

Common side effects of Vasopressin intravenous infusion include Hypertension, Coronary vasoconstriction / myocardial ischemia, Arrhythmias, Hyponatremia (water intoxication), Abdominal cramping, Pallor / peripheral vasoconstriction.

What does Vasopressin intravenous infusion target?

Vasopressin intravenous infusion targets Vasopressin receptor V1a, V1b, and V2 and is a Vasopressor agent; antidiuretic hormone.

Related